Econ Financial Services Corp Acquires 15,836 Shares of Edwards Lifesciences Corporation $EW

Econ Financial Services Corp lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 139.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,198 shares of the medical research company’s stock after purchasing an additional 15,836 shares during the quarter. Econ Financial Services Corp’s holdings in Edwards Lifesciences were worth $2,115,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $266,000. Trexquant Investment LP acquired a new position in Edwards Lifesciences in the 1st quarter worth $2,472,000. State of Wyoming increased its holdings in Edwards Lifesciences by 38.3% during the 1st quarter. State of Wyoming now owns 2,676 shares of the medical research company’s stock worth $194,000 after purchasing an additional 741 shares in the last quarter. Graham Capital Management L.P. acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $1,082,000. Finally, Focus Partners Advisor Solutions LLC lifted its holdings in shares of Edwards Lifesciences by 76.2% in the first quarter. Focus Partners Advisor Solutions LLC now owns 7,389 shares of the medical research company’s stock valued at $535,000 after purchasing an additional 3,195 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW opened at $85.26 on Friday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $84.62 and its 200 day simple moving average is $79.87. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a market cap of $49.48 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 3.83 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the sale, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 45,465 shares of company stock worth $3,804,610. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Stifel Nicolaus set a $100.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Friday, December 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Finally, National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $93.95.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.